StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to “Hold”

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other analysts also recently weighed in on the company. Chardan Capital restated a “buy” rating and set a $2.50 price objective on shares of ProQR Therapeutics in a research report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of ProQR Therapeutics in a research report on Friday, May 10th. Finally, Citigroup increased their target price on ProQR Therapeutics from $1.80 to $2.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $3.38.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $1.66 on Friday. The stock has a market capitalization of $135.06 million, a price-to-earnings ratio of -4.49 and a beta of 0.35. The stock’s 50 day moving average price is $1.88 and its two-hundred day moving average price is $2.04. ProQR Therapeutics has a 52 week low of $1.11 and a 52 week high of $3.29.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. ProQR Therapeutics had a negative return on equity of 61.58% and a negative net margin of 260.75%. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.31 million. On average, equities research analysts forecast that ProQR Therapeutics will post -0.37 EPS for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PRQR. RFG Advisory LLC acquired a new stake in shares of ProQR Therapeutics in the first quarter valued at about $73,000. BNP Paribas Financial Markets increased its stake in shares of ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 19,100 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of ProQR Therapeutics in the first quarter valued at about $56,000. EP Wealth Advisors LLC acquired a new stake in ProQR Therapeutics during the first quarter worth approximately $26,000. Finally, Ikarian Capital LLC grew its stake in ProQR Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock worth $1,098,000 after purchasing an additional 10,958 shares during the period. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).